Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes
What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
Back Thorens, B, Porret, A, Bhler, L, et al (Nov 1993) Cloning and functional expression of the human islet GLP-1 receptor
Gross margin was 65% for the first quarter of 2026 compared to 73% for the first quarter of 2025
Individual market Table 1 shows the 13 states where at least one marketplace plan covers Wegovy for obesity
